VV119

Phase 2Small molecule

VVigonvita Life Sciences

VV119 is one of 41 small molecule programs targeting Schizophrenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchizophreniaNot yet recruiting

SchizophreniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Preclinical

1 2

Resotran

Takeda

Preclinical

1 3

Inapsine

Jazz Pharmaceuticals

Preclinical

1 4

Depakote

Ibrance

Lunesta

3 7

Luvox

SSolvay Pharmaceuticals

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Rapamune

PPrism Pharmaceuticals

Preclinical

1 10

Persantine

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Study completion

NCT07240636

Phase 1Active, not recruiting

Schizophrenia

NCT06105151

Phase 1Recruiting

Schizophrenia

NCT06504290

Q4 2027

Phase 2Not yet recruiting

Schizophrenia

NCT07703956

Clinical

Trials by Indication[1]

Schizophrenia3 trials

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers

Active, not recruiting·VVigonvita Life Sciences·Phase 1·NCT06105151·82 enrolled

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VV119 Capsules With Multiple Ascending Doses in Chinese Healthy Adult Subjects and Patients With Schizophrenia

Recruiting·VVigonvita Life Sciences·Phase 1·NCT06504290·40 enrolled

A Phase 2,Multicenter, Randomized, Double-blind, Placebo and Active Comparator Parallel-controlled Study to Evaluate the Safety and Efficacy of VV119 in Adults With Acute Schizophrenia

Not yet recruiting·VVigonvita Life Sciences·Phase 2·NCT07703956·500 enrolled

Unspecified1 trial

Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers

Recruiting·VVigonvita Life Sciences·Phase 1·NCT07240636·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VV119. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VV119 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VV119. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vigonvita Life Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVigonvita Life Sciences

VV119

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Schizophrenia3 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News